Revive Therapeutics a company focused on the research, development and commercialisation of novel treatments for serious and unmet medical needs, announced Dr Arun Sanyal will join the Company as a Scientific Advisor for cannabinoid-based therapeutics targeting liver diseases.
Craig Leon, CEO of Revive, said: "I am pleased Dr Sanyal has joined Revive to assist with advancing the research and clinical development of our cannabinoid-based research initiatives targeting liver diseases. Dr Sanyal will be valuable in guiding our liver diseases product pipeline in a number of indications including liver cirrhosis, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease."
Sanyal said: "I look forward to working with Revive Therapeutics on the broad areas of hepatic inflammation, fibrosis and cirrhosis particularly in the context of non-alcoholic fatty liver disease. I am particularly pleased to be working on the role of the cannabinoid system and non-alcoholic fatty liver disease, two areas of long standing research interest for me."
Sanyal has developed, mediated and encouraged global liver research as a physician-scientist for 25 years. Currently, Sanyal is Professor of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine. His research has spanned the spectrum of translational science in liver cirrhosis, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
Sanyal is a special Council Board Member of National Institute on Alcohol Abuse and Alcoholism (NIAAA) and has been a past President of the American Association for the Study of Liver Diseases (AASLD). He has chaired committees at the NIDDK NASH clinical research network and the NIH hepatobiliary study section.
He was instrumental in establishing the Liver Forum for NASH and he is also leading several major drug trials for the treatment of NASH. He has published over 300 papers in leading medical journals and periodicals throughout his career.
